Work

Abstract 298: Amplification of mutant ERBB2 drives resistance to the irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer patients

Year: 2016

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2016-298

Authors: F Javier Carmona, David Hyman, Gary Ulaner, Joe Erinjeri, Nancy Bouvier, Helen Won, Richard Cutler, Al Alani, Michael Berger, José Baselga, Maurizio Scaltriti

Institutions: Memorial Sloan Kettering Cancer Center, Puma Biotechnology (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2481184265

Cites:

Cited by: 1

Related to: 10